Core Viewpoint - Milestone Pharmaceuticals has successfully expanded access to its product CARDAMYST™ (etripamil) nasal spray through its inclusion in Express Scripts' national formularies, enhancing affordability and accessibility for patients with paroxysmal supraventricular tachycardia (PSVT) across the United States [1][3]. Company Overview - Milestone Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing innovative cardiovascular medicines, with CARDAMYST as its lead product [16]. - The company aims to provide effective treatment options for patients suffering from heart conditions, particularly PSVT [16]. Product Information - CARDAMYST is the first FDA-approved self-administered nasal spray for converting acute symptomatic episodes of PSVT to sinus rhythm in adults [2][5]. - The product is designed as a rapid response therapy, allowing patients to manage their condition without immediate medical oversight [5]. - CARDAMYST has undergone a robust clinical trial program, including a completed Phase 3 clinical-stage program for PSVT treatment [5]. Market Impact - The addition of CARDAMYST to Express Scripts' formularies marks a significant milestone as it is the first major payor to accept the product, which is expected to improve patient access to this treatment option [3]. - Approximately two million people in the U.S. are diagnosed with PSVT, indicating a substantial market potential for CARDAMYST [4]. Future Development - Milestone Pharmaceuticals is committed to further expanding access to CARDAMYST and is actively engaging with other insurance providers to increase coverage [3]. - Etripamil, the active ingredient in CARDAMYST, is also in development for treating PSVT in pediatric patients and for controlling acute atrial fibrillation with rapid ventricular rate in adults [5].

Core Insights - Milestone Pharmaceuticals Inc. reported an earnings beat for Q4 2025, with an EPS of -$0.16, surpassing estimates and reflecting controlled expenses and initial revenue from licensing and launch activities post-FDA approval [3][8] - The company is advancing the commercialization of its lead product, CARDAMYST™ (etripamil), which is the first FDA-approved self-administered treatment for acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) [2] Financial Performance - Revenue for Q4 2025 was approximately $1.5 million, exceeding the lower consensus estimate of around $1.2 million but falling short of higher outlier estimates [3][8] - The company continues to exhibit typical biotech financial metrics, including a negative P/E ratio of around -1.44 and high price-to-sales ratios, reflecting investor expectations for future growth [5] Regulatory Developments - The European Medicines Agency (EMA) is currently reviewing the Marketing Authorization Application (MAA) for etripamil, with a decision now expected in the first half of 2027, a delay from the initial Q1 2027 projection [4][8] - This adjustment in the European regulatory timeline has contributed to stock volatility, although the U.S. launch momentum remains a positive factor [4] Liquidity and Future Outlook - Milestone Pharmaceuticals maintains a strong liquidity position, with a current ratio reported around 8.0–8.2, indicating solid short-term asset coverage of liabilities [6] - Pro forma cash reserves are expected to support operations into 2027, providing a runway for the U.S. launch of CARDAMYST, further pipeline development, and ongoing regulatory efforts [6][7] Market Position and Investor Sentiment - Despite facing typical biotech challenges such as limited near-term revenue and regulatory timing adjustments, the earnings beat and initial sales traction highlight the company's resilience and potential upside from the recent FDA approval and commercial rollout [7] - Investors are advised to monitor the progress of the U.S. launch and any further updates from the EMA regarding the European approval timeline for 2027 [7]

Core Insights - Milestone Pharmaceuticals reported financial results for Q4 and full year 2025, highlighting the FDA approval and launch of CARDAMYST™ (etripamil) nasal spray for treating paroxysmal supraventricular tachycardia (PSVT) [1][5][6] Financial Performance - The company received a $75 million payment under a Royalty Purchase Agreement related to the FDA approval of CARDAMYST [12] - As of December 31, 2025, Milestone had cash and short-term investments of $106 million, up from $69.7 million in 2024 [13] - The company recorded $1.5 million in revenue for 2025, primarily from a milestone payment related to CARDAMYST's approval [13] - Research and development expenses for 2025 were $18.1 million, an increase from $14.4 million in 2024, driven by higher consulting costs [13][14] - The net loss for Q4 2025 was $17.4 million, or $0.16 per share, compared to a net loss of $12.4 million, or $0.19 per share, in Q4 2024 [14] Product Launch and Market Engagement - The commercial launch of CARDAMYST is tracking or exceeding pre-launch expectations, with a national sales force fully deployed within eight weeks of FDA approval [2][5] - Initial engagement with healthcare providers and payers has been positive, indicating strong demand for CARDAMYST [2][5] - CARDAMYST is the first new treatment option for PSVT in 30 years, with clinical studies showing participants were twice as likely to convert symptomatic PSVT to sinus rhythm compared to placebo [5][6] Regulatory and Development Updates - The marketing authorization application for etripamil nasal spray in Europe has been accepted, with a decision expected by the first half of 2027 [6] - A Phase 3 program for etripamil in patients with atrial fibrillation with rapid ventricular rate (AFib-RVR) is planned, following FDA guidance [8] Corporate Updates - David Sandoval was appointed as General Counsel and Chief Compliance Officer, bringing over 15 years of experience in the life sciences sector [10]

Core Insights - Milestone Pharmaceuticals announced a moderated poster presentation on the minimal blood pressure effects of intranasal etripamil for treating paroxysmal supraventricular tachycardia (PSVT) at the 2026 American College of Cardiology Annual Scientific Session [1][4] - Etripamil, a novel calcium channel blocker, was FDA-approved in December 2025 as the first self-administered treatment for symptomatic PSVT in adults [6][9] Data Highlights - The Phase 3 trials showed that etripamil had minimal impact on blood pressure, with a mean systolic BP change of 1.8 mmHg (SD 11.2) for a single 70 mg dose and 0.0 mmHg (SD 12.0) for repeat doses [6] - Among 1,610 patients, treatment-emergent adverse events (TEAEs) of hypotension were 0.4% (N=7) and syncope were 0.2% (N=4), with all TEAEs resolving without medical intervention [6] Presentation Details - The moderated poster presentation will be held on March 29, 2026, at 10:06 AM CT, presented by Dr. Narendra Singh [4] - An Expert Theater session will also explore CARDAMYST as an emerging therapy for symptomatic PSVT episodes [4] About CARDAMYST - CARDAMYST (etripamil) is designed for self-administration, allowing patients to manage acute symptomatic episodes of PSVT without immediate medical oversight [9] - The product is currently in Phase 2 development for pediatric patients and Phase 3 for atrial fibrillation with rapid ventricular rate [9]

Core Insights - Milestone Pharmaceuticals Inc. will present at the TD Cowen 46th Annual Health Care Conference from March 2-4, 2026 [1] - A live webcast of the presentation will be available on March 3 at 9:10 AM EST, with a replay accessible for approximately 90 days [2] Company Overview - Milestone Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative cardiovascular medicines for individuals with specific heart conditions [3] - The company's lead product, CARDAMYST™ (etripamil) nasal spray, is an FDA-approved treatment for converting acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults [3] - Etripamil is also under development for treating symptomatic episodic attacks associated with atrial fibrillation with rapid ventricular response (AFib-RVR) [3]

Core Insights - Milestone Pharmaceuticals has appointed David Sandoval as General Counsel and Chief Compliance Officer, coinciding with the launch of CARDAMYST™ (etripamil) nasal spray, the first self-administered treatment for acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) in adults [1][3] Company Overview - Milestone Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing innovative cardiovascular medicines, with CARDAMYST™ as its lead product [16] - CARDAMYST™ is a novel calcium channel blocker nasal spray approved by the FDA for converting acute symptomatic episodes of PSVT to sinus rhythm in adults [5][16] Product Details - CARDAMYST™ is designed as a self-administered rapid response therapy, allowing patients to manage their condition without immediate medical oversight [5] - The product has undergone a robust clinical trial program, including a completed Phase 3 clinical-stage program for PSVT treatment [6] Leadership Appointment - David Sandoval brings over 15 years of experience in legal and compliance functions within the life sciences sector, focusing on late-stage development and regulatory approval [2] - His previous roles include Senior Vice President and General Counsel at MaxCyte, where he oversaw global legal and compliance activities and played a key role in strategic transactions [2][4] Strategic Importance - The appointment of Mr. Sandoval is seen as critical for Milestone as it prepares for the commercialization of CARDAMYST, with expectations of scaling operations and building infrastructure for long-term growth [3]

Core Insights - Milestone Pharmaceuticals has launched its first commercial product, CARDAMYST™ (etripamil) nasal spray, for the treatment of paroxysmal supraventricular tachycardia (PSVT) in adults, now available through U.S. retail pharmacies [2][4][8] - The FDA approved CARDAMYST on December 12, 2025, marking the first new treatment for PSVT in over 30 years [6] Product Launch and Support - CARDAMYST will be supported by a patient assistance platform that includes benefits verification, reimbursement support, and copay assistance, with copays capped at $25 for eligible commercially insured patients [3][5] - A national sales force is set to be deployed in mid-February 2026 to promote the product [2][5] Patient Impact and Market Need - Approximately two million people in the U.S. are diagnosed with PSVT, which causes episodes of rapid heartbeats and can significantly impact daily life [7] - The availability of CARDAMYST provides patients with a self-administered treatment option, allowing for on-demand care and greater control over their condition [4][8] Clinical Background - CARDAMYST is a novel calcium channel blocker designed for rapid response therapy, bypassing the need for immediate medical oversight [8] - The product has undergone a robust clinical trial program, including a completed Phase 3 clinical-stage program for PSVT [8]

Core Insights - Milestone Pharmaceuticals has received FDA approval for CARDAMYST™ (etripamil) nasal spray, marking the first new treatment for paroxysmal supraventricular tachycardia (PSVT) in over 30 years, providing a self-administered option for over two million Americans with this condition [1][4][12] Company Overview - Milestone Pharmaceuticals is a biopharmaceutical company focused on developing innovative cardiovascular medicines, with CARDAMYST being its lead product aimed at treating PSVT [27] Product Details - CARDAMYST is a rapid-acting calcium channel blocker designed for the conversion of acute symptomatic episodes of PSVT to sinus rhythm in adults, allowing patients to manage episodes independently [3][14] - The product is expected to be available in retail pharmacies in the first quarter of 2026 [1] Clinical Data - The FDA approval is supported by a clinical trial program involving over 1,800 participants and more than 2,000 PSVT episodes, demonstrating that CARDAMYST users were twice as likely to convert to sinus rhythm compared to placebo [6][7] - In the Phase 3 RAPID trial, 64% of participants using CARDAMYST converted to sinus rhythm within 30 minutes, compared to 31% for placebo, with a median conversion time of 17 minutes for CARDAMYST versus 54 minutes for placebo [6][7] Market Potential - The approval of CARDAMYST opens the door for further development of etripamil for atrial fibrillation with rapid ventricular rate (AFib-RVR) under a supplemental New Drug Application (sNDA) pathway, targeting an estimated market of three to four million patients by 2030 [4][10][13] Financial Position - As of September 30, 2025, Milestone had cash and equivalents of $82.6 million, positioning the company well for the launch and commercialization of CARDAMYST [22] - The company has entered into a Royalty Purchase Agreement to secure additional funding contingent upon the FDA approval of etripamil [22][23]

Core Insights - Milestone Pharmaceuticals is preparing for the potential launch of CARDAMYST (etripamil) nasal spray for treating symptomatic paroxysmal supraventricular tachycardia (PSVT) with a PDUFA target date set for December 13, 2025 [1][6] - The company has strengthened its financial position through a successful equity offering and an amended Royalty Purchase Agreement, providing resources for a successful launch [2][5] - Etripamil is also being developed for atrial fibrillation with rapid ventricular rate (AFib-RVR), with plans for a pivotal Phase 3 program following positive Phase 2 trial results [4][9] Financial Overview - As of September 30, 2025, Milestone reported cash and cash equivalents of $82.6 million, an increase from $69.7 million at the end of 2024 [12] - The company reported a net loss of $11.9 million for the third quarter of 2025, compared to a net loss of $9.4 million in the same period of 2024 [12][18] - Research and development expenses for the third quarter of 2025 were $3.9 million, slightly down from $4.0 million in the prior year [12][18] Clinical Development - Etripamil has shown promising efficacy and safety in clinical trials, with data from over 600 patients indicating higher conversion rates for symptomatic PSVT compared to placebo [6] - The company plans to leverage data from the PSVT NDA for the supplemental NDA regulatory approval pathway for AFib-RVR [4][6] - Recent presentations at the American Heart Association (AHA) Scientific Sessions highlighted the potential of etripamil as a rapid, self-administered treatment option [6][9]